DGIdb - RIGOSERTIB Drug Record

RIGOSERTIB chembl:CHEMBL1241855 Antineoplastic

Alternate Names:

RIGOSERTIB
ON-01910

Drug Info:

FDA Approval	not approved
Drug Class	small molecule
Drug Indications	antineoplastic agent

(3 More Sources)

Publications:

Franco et al., 2014, CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer., Oncotarget
Athuluri-Divakar et al., 2016, A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling., Cell
Anderson et al., 2013, The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas., Mol. Cancer Ther.
O'Neil et al., 2015, A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer., Ann. Oncol.

RIGOSERTIB CDKN2A

Interaction Score: 0.65

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy ON-01910 + PD0332991

Indication/Tumor Type pancreatic cancer

Response Type decreased response

PMIDs:
25156567

Sources:
JAX-CKB
RIGOSERTIB HRAS

Interaction Score: 0.42

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
27104980

Sources:
JAX-CKB
RIGOSERTIB PIK3CA

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Novel Target

Trial Name ON 01910.Na,Estybon

Indication/Tumor Type head and neck squamous cell carcinoma

PMIDs:
27104980 23873848

Sources:
TdgClinicalTrial JAX-CKB
RIGOSERTIB KRAS

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type pancreatic cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
27104980 26091808

Sources:
JAX-CKB
RIGOSERTIB PIK3CD

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name ON 01910.Na,Estybon

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial
RIGOSERTIB PIK3CB

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name ON 01910.Na,Estybon

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial
RIGOSERTIB PLK1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name ON 01910.Na,Estybon

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial TTD
RIGOSERTIB PIK3CG

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
RIGOSERTIB PTEN

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase I

Response Type predicted – sensitive

PMIDs:
None found

Sources:
JAX-CKB

TdgClinicalTrial: RIGOSERTIB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class small molecule

FDA Approval not approved

Publications:

JAX-CKB: rigosertib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Athuluri-Divakar et al., 2016, A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling., Cell

Anderson et al., 2013, The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas., Mol. Cancer Ther.

JAX-CKB: ON-01910
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Franco et al., 2014, CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer., Oncotarget

JAX-CKB: Rigosertib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

O'Neil et al., 2015, A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer., Ann. Oncol.

TALC: RIGOSERTIB
- Version: 12-May-2016
Alternate Names:

RIGOSERTIB Primary Drug Name

RIGOSERTIB Drug Generic Name

ESTYBON Drug Trade Name

Drug Info:

Publications:
TTD: Rigosertib
- Version: 2020.06.01
Alternate Names:

D0KF9Q TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1241855
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

combination therapy	ON-01910 + PD0332991
Indication/Tumor Type	pancreatic cancer
Response Type	decreased response

Indication/Tumor Type	Advanced Solid Tumor
Response Type	sensitive
Approval Status	Preclinical - Cell culture

Novel drug target	Novel Target
Trial Name	ON 01910.Na,Estybon
Indication/Tumor Type	head and neck squamous cell carcinoma

Evidence Type	Actionable
Approval Status	Phase I
Response Type	predicted – sensitive

RIGOSERTIB	Primary Drug Name
RIGOSERTIB	Drug Generic Name
ESTYBON	Drug Trade Name

RIGOSERTIB Drug Record

RIGOSERTIB chembl:CHEMBL1241855 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info: combination therapy ON-01910 + PD0332991 Indication/Tumor Type pancreatic cancer Response Type decreased response

PMIDs: 25156567

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type sensitive Approval Status Preclinical - Cell culture

PMIDs: 27104980

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Novel drug target Novel Target Trial Name ON 01910.Na,Estybon Indication/Tumor Type head and neck squamous cell carcinoma

PMIDs: 27104980 23873848

Sources: TdgClinicalTrial JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type pancreatic cancer Response Type sensitive Approval Status Preclinical

PMIDs: 27104980 26091808

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Trial Name ON 01910.Na,Estybon Novel drug target Novel Target

PMIDs: None found

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Trial Name ON 01910.Na,Estybon Novel drug target Novel Target

PMIDs: None found

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Trial Name ON 01910.Na,Estybon Novel drug target Novel Target

PMIDs: None found

Sources: TdgClinicalTrial TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Phase I Response Type predicted – sensitive

PMIDs: None found

Sources: JAX-CKB

TdgClinicalTrial: RIGOSERTIB

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class small molecule FDA Approval not approved

Publications:

JAX-CKB: rigosertib

Alternate Names:

Drug Info:

JAX-CKB: ON-01910

Alternate Names:

Drug Info:

Publications: Franco et al., 2014, CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer., Oncotarget

JAX-CKB: Rigosertib

Alternate Names:

Drug Info:

Publications: O'Neil et al., 2015, A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer., Ann. Oncol.

TALC: RIGOSERTIB

Alternate Names: RIGOSERTIB Primary Drug Name RIGOSERTIB Drug Generic Name ESTYBON Drug Trade Name

Drug Info:

Publications:

TTD: Rigosertib

Alternate Names: D0KF9Q TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1241855

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy ON-01910 + PD0332991

Indication/Tumor Type pancreatic cancer

Response Type decreased response

PMIDs:
25156567

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
27104980

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Novel Target

Trial Name ON 01910.Na,Estybon

Indication/Tumor Type head and neck squamous cell carcinoma

PMIDs:
27104980 23873848

Sources:
TdgClinicalTrial JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type pancreatic cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
27104980 26091808

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name ON 01910.Na,Estybon

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name ON 01910.Na,Estybon

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name ON 01910.Na,Estybon

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase I

Response Type predicted – sensitive

PMIDs:
None found

Sources:
JAX-CKB

Drug Info:

Drug Indications antineoplastic agent

Drug Class small molecule

FDA Approval not approved

Publications:

Franco et al., 2014, CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer., Oncotarget

Publications:

O'Neil et al., 2015, A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer., Ann. Oncol.

Alternate Names:

RIGOSERTIB Primary Drug Name

RIGOSERTIB Drug Generic Name

ESTYBON Drug Trade Name

Alternate Names:

D0KF9Q TTD Drug ID